Diabetes Research and Clinical Practice
Volume 75, Issue 3 , Pages 320-326, March 2007

Hepatitis C, metabolic syndrome, and inflammatory markers: Results from the Third National Health and Nutrition Examination Survey [NHANES III]

  • Magda Shaheen

      Affiliations

    • Department of Internal Medicine, Charles R. Drew University of Medicine and Science, 12021 South Wilmington Avenue Los Angeles, CA 90059, United States
    • Corresponding Author InformationCorresponding author. Tel.: +1 310 761 4727; fax: +1 310 631 1495.
  • ,
  • Diana Echeverry

      Affiliations

    • Department of Internal Medicine, Charles R. Drew University of Medicine and Science, 12021 South Wilmington Avenue Los Angeles, CA 90059, United States
  • ,
  • Marcela Garcia Oblad

      Affiliations

    • Department of Internal Medicine, Charles R. Drew University of Medicine and Science, 12021 South Wilmington Avenue Los Angeles, CA 90059, United States
  • ,
  • Marie I. Montoya

      Affiliations

    • Department of Internal Medicine, Charles R. Drew University of Medicine and Science, 12021 South Wilmington Avenue Los Angeles, CA 90059, United States
  • ,
  • Senait Teklehaimanot

      Affiliations

    • Department of Family Medicine, Charles R. Drew University of Medicine and Science, 12021 South Wilmington Avenue Los Angeles, CA 90059, United States
  • ,
  • Abbasi J. Akhtar

      Affiliations

    • Department of Internal Medicine, Charles R. Drew University of Medicine and Science, 12021 South Wilmington Avenue Los Angeles, CA 90059, United States

Received 11 February 2006; accepted 11 July 2006. published online 18 August 2006.

Abstract 

Studies have shown that hepatitis C (HCV) is associated with type 2 diabetes mellitus (DM2) possibly due to insulin resistance and inflammation. Metabolic syndrome is a risk factor for DM2. Our objectives were to assess the relationship between HCV and metabolic syndrome and inflammatory markers. We used data from The Third National Health Nutrition and Examination Survey (NHANES-III). We excluded pregnant women, subjects with diabetes, those taking non-steroidal anti-inflammatory drugs, and those diagnosed with concomitant infection. We analyzed the data controlling for demographic variables, body mass index, use of contraceptives, had arthritis, and had gout. Among the 10,383 subjects, 2.3% had HCV and 16.7% had metabolic syndrome using the ATP III criteria. After controlling for the confounders, HCV was not associated with metabolic syndrome but associated with HOMA insulin resistance and inflammatory marker ferritin. Among subjects with both HCV and metabolic syndrome, the adjusted HOMA insulin level was higher than those without HCV and metabolic syndrome. In addition, the serum ferritin level was a strong predictor of HOMA insulin resistance. In clinical practice, serum ferritin can be obtained along with routine blood tests in any laboratory, and it has a potential to be a surrogate marker of insulin resistance in people with HCV and metabolic syndrome.

Keywords: Hepatitis C, Metabolic syndrome, Inflammatory markers

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This work was supported in part by G12-RR03026-19, P20-RR11145, U54 RR019234, U54 RR14616 NIH/NCRR and P20MD000182-02 from the NIH/NCMHD.

PII: S0168-8227(06)00308-1

doi:10.1016/j.diabres.2006.07.008

Diabetes Research and Clinical Practice
Volume 75, Issue 3 , Pages 320-326, March 2007